on BioNxt Solutions Inc. (isin : CA0909741062)
BioNxt Expands Sublingual Product Pipeline with Innovations
BioNxt Solutions Inc., a bioscience company, has announced the expansion of its product pipeline. The company focuses on next-generation drug delivery systems like Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablet). These systems target autoimmune diseases such as Multiple Sclerosis, Myasthenia Gravis, Lupus Nephritis, and Rheumatoid Arthritis. Additionally, BioNxt is entering the longevity market with solutions aimed at anti-aging.
Key products include BNT23001, a sublingual Cladribine for Multiple Sclerosis, and a similar approach for Myasthenia Gravis. For Lupus Nephritis, BioNxt is developing a thin-film product to increase bioavailability. Their Rheumatoid Arthritis solution uses both sublingual and oral technologies.
In the anti-aging sector, BioNxt is developing pharmaceuticals addressing aging factors to enhance health and longevity. These efforts highlight BioNxt's commitment to patient-friendly therapeutic advancements. CEO Hugh Rogers emphasizes their role in addressing unmet medical needs and fostering growth.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all BioNxt Solutions Inc. news